Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;24(11):1126-1136.
doi: 10.1111/hiv.13542. Epub 2023 Oct 18.

Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023

Juan Ambrosioni  1   2 , Laura Levi  3 , Jasmini Alagaratnam  4   5 , Kathrin Van Bremen  6 , Andrea Mastrangelo  7 , Hylke Waalewijn  8 , Jean-Michel Molina  3 , Giovanni Guaraldi  9 , Alan Winston  5 , Christoph Boesecke  6 , Paola Cinque  10 , Alasdair Bamford  11 , Alexandra Calmy  12 , Catia Marzolini  13   14   15 , Esteban Martínez  1   2 , Cristiana Oprea  16 , Steven Welch  17 , Anna Koval  18 , Luis Mendao  19 , Jürgen K Rockstroh  6 ; EACS Governing Board
Affiliations

Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023

Juan Ambrosioni et al. HIV Med. 2023 Nov.

Abstract

Background: The European AIDS Clinical Society (EACS) guidelines were revised in 2023 for the 19th time, and all aspects of HIV care were updated.

Key points of the guidelines update: Version 12.0 of the guidelines recommend the same six first-line treatment options for antiretroviral treatment (ART)-naïve adults as versions 11.0 and 11.1: tenofovir-based backbone plus an unboosted integrase inhibitor or doravirine; abacavir/lamivudine plus dolutegravir; or dual therapy with lamivudine or emtricitabine plus dolutegravir. The long-acting section has been expanded in the ART and drug-drug interaction (DDI) panels. Tables for preferred and alternative ART in children and adolescents have been updated, as has the section on prevention of vertical transmission, particularly with new guidance for breastfeeding. A new DDI table has been included for the ART and anti-infective drugs used for opportunistic infections, sexually transmitted infections, and other infectious conditions; lenacapavir has been included in all DDI tables. New sections on alcohol use and patient-reported outcome measures (PROMs) have been included in the comorbidity panel, in addition to updates on many relevant topics, such as new resource guidance for deprescribing in people with HIV. Other sections, including travel, cognitive impairment, cancer screening, sexual health, and diabetes have also been revised extensively. The algorithm for the management of acute hepatitis C virus infection has been removed, as current guidelines recommend immediate treatment of all people with recently acquired hepatitis C virus. Updates on vaccination for hepatitis B virus and recommendations for simplification to tenofovir-free two-drug regimens in people with isolated anti-hepatitis B core antibodies are provided. In the opportunistic infections and COVID-19 panel, guidance on the management of COVID-19 in people with HIV has been updated according to the most up-to-date evidence, and a new section on monkeypox has been added.

Conclusions: In 2023, the EACS guidelines were updated extensively and now include several new sections. The recommendations are available as a free app, in interactive web format, and as a pdf online.

Keywords: ART; EACS; HIV; Mpox; V12.0; guidelines; major updates; European AIDS Clinical Society; antiretroviral therapy.

PubMed Disclaimer

References

REFERENCES

    1. Ryom L, De Miguel R, Cotter AG, et al. Major revision version 11.0 of the European AIDS clinical society guidelines 2021. HIV Med. 2022;23:849-858.
    1. https://www.eacsociety.org/guidelines/eacs-guidelines/.
    1. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and Rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 (HIV-1) infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis. 2023;76:1646-1654. doi:10.1093/cid/ciad020
    1. Orkin C, Schapiro JM, Perno CF, et al. Expanded multivariable models to assist patient selection for long-acting cabotegravir + Rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure. Clin Infect Dis. 2023. doi:10.1093/cid/ciad370
    1. Chinula L, Ziemba L, Brummel S, et al. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet HIV. 2023;10:e363-e374.